Expression and Functional Significance of an Additional Ligand for CTLA-4
Overview
Affiliations
Effective T-cell activation requires antigen/major histocompatibility complex engagement by the T-cell receptor complex in concert with one or more costimulatory molecules. Recent studies have suggested that the B7 molecule, expressed on most antigen presenting cells, functions as a costimulatory molecule through its interaction with CD28 on T cells. Blocking the CD28/B7 interaction with CTLA4Ig inhibits T-cell activation in vitro and induces unresponsiveness. We demonstrate that another molecule(s), termed B7-2, is expressed constitutively on dendritic cells, is differentially regulated on B cells, and costimulates naive T cells responding to alloantigen. B7-2 is up-regulated by lipopolysaccharide in < 6 hr and is maximally expressed on the majority of B cells by 24 hr. In contrast, B7 is detected only on a subset of activated B cells late (48 hr) after stimulation. In addition, Con A directly induces B7-2 but not B7 expression on B cells. Finally, although both anti-B7 monoclonal antibodies and CTLA4Ig blocked T-cell proliferation to antigen-expressing B7 transfectants, only CTLA4Ig had any significant inhibitory effect on T-cell proliferation to antigens expressed on natural antigen presenting cells, such as dendritic cells. Thus, B7 is not the only costimulatory molecule capable of initiating T-cell responses since a second ligand, B7-2, can provide a necessary second signal for T-cell activation.
Neoadjuvant chemoradiotherapy up-regulates PD-L1 in radioresistant colorectal cancer.
Bae S, Lee H, Park J, Seo I, Cho J, Kim J Clin Transl Radiat Oncol. 2025; 51():100906.
PMID: 39811542 PMC: 11732604. DOI: 10.1016/j.ctro.2024.100906.
Utilising an in silico model to predict outcomes in senescence-driven acute liver injury.
Ashmore-Harris C, Antonopoulou E, Aird R, Man T, Finney S, Speel A NPJ Regen Med. 2024; 9(1):26.
PMID: 39349489 PMC: 11442582. DOI: 10.1038/s41536-024-00371-1.
A spatiotemporal map of co-receptor signaling networks underlying B cell activation.
Susa K, Bradshaw G, Eisert R, Schilling C, Kalocsay M, Blacklow S Cell Rep. 2024; 43(6):114332.
PMID: 38850533 PMC: 11256977. DOI: 10.1016/j.celrep.2024.114332.
Aging-related biomarker discovery in the era of immune checkpoint inhibitors for cancer patients.
Al-Danakh A, Safi M, Jian Y, Yang L, Zhu X, Chen Q Front Immunol. 2024; 15:1348189.
PMID: 38590525 PMC: 11000233. DOI: 10.3389/fimmu.2024.1348189.
Blocking Superantigen-Mediated Diseases: Challenges and Future Trends.
Wang P, Fredj Z, Zhang H, Rong G, Bian S, Sawan M J Immunol Res. 2024; 2024:2313062.
PMID: 38268531 PMC: 10807946. DOI: 10.1155/2024/2313062.